Literature DB >> 21146808

Peripheral kappa opioid receptors activation reduces alveolar bone loss in rats by modulating interleukin-6 and -10.

Jasílio Vilela Bastos1, Celso Martins Queiroz-Junior, Marcelo Vidigal Caliari, Janetti Nogueira Francischi, Cinthia Mara da Fonseca Pacheco, Kátia Lucy de Melo Maltos.   

Abstract

OBJECTIVE: The beneficial effects of kappa opioid agonist U-50,488 in preventing periodontal disease (PD) progression in rats have already been described, but its mechanism of action is unknown. The present study evaluated the expression of TNF-α, IL-6, IL-8 and IL-10 in the gingival tissues of rats with ligature-induced PD, treated with U-50,488. It also correlated the effects of this agonist with myeloperoxidase (MPO) activity and the presence of osteoclasts.
DESIGN: Male Holtzman rats weighing 250-300 g were divided into four groups: (1) control, (2) ligature, (3) ligature+saline and (4) ligature+kappa agonist. Experimental PD was induced by placing a sterile silk ligature around the 2nd left upper molar. Rats from groups 3 to 4 were locally administered with either saline or U-50,488, respectively, from day 3 to day 5 following ligation. After 5 or 11 days, the rats were euthanized and periodontal tissue samples were collected for histological and morphometric analysis and for determination of TNF-α, IL-6, IL-8, IL-10 and MPO.
RESULTS: Ligature placement induced significant alveolar bone loss. The number of osteoclasts, degree of MPO activity, IL-6, IL-8 and TNF-α expression were also increased by PD. U-50,488 reduced both bone loss and the number of osteoclasts, but did not alter histological inflammatory infiltrate or MPO activity. U-50,488 significantly reduced IL-6 and increased IL-10 levels, but did not affect TNF-α and IL-8.
CONCLUSION: Lowering the levels of IL-6 and increasing IL-10 are important mechanisms by which U-50,488 reduces alveolar bone loss in ligature-induced periodontal disease.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21146808     DOI: 10.1016/j.archoralbio.2010.11.012

Source DB:  PubMed          Journal:  Arch Oral Biol        ISSN: 0003-9969            Impact factor:   2.633


  5 in total

1.  Effects of peripheral κ opioid receptor activation on inflammatory mechanical hyperalgesia in male and female rats.

Authors:  Q-Schick Auh; Jin Y Ro
Journal:  Neurosci Lett       Date:  2012-07-20       Impact factor: 3.046

2.  Nalbuphine, a kappa opioid receptor agonist and mu opioid receptor antagonist attenuates pruritus, decreases IL-31, and increases IL-10 in mice with contact dermatitis.

Authors:  Saadet Inan; Alvaro Torres-Huerta; Liselotte E Jensen; Nae J Dun; Alan Cowan
Journal:  Eur J Pharmacol       Date:  2019-09-27       Impact factor: 4.432

3.  Local kappa opioid receptor activation decreases temporomandibular joint inflammation.

Authors:  Tânia C Chicre-Alcântara; Karla E Torres-Chávez; Luana Fischer; Juliana T Clemente-Napimoga; Vilma Melo; Carlos Amílcar Parada; Claudia Herrera Tambeli
Journal:  Inflammation       Date:  2012-02       Impact factor: 4.092

4.  Kappa opioid receptor signaling protects cartilage tissue against posttraumatic degeneration.

Authors:  Ling Wu; Shu Zhang; Ruzanna Shkhyan; Siyoung Lee; Francesca Gullo; Claire D Eliasberg; Frank A Petrigliano; Kai Ba; Jing Wang; Yunfeng Lin; Denis Evseenko
Journal:  JCI Insight       Date:  2017-01-12

5.  Opioid receptor agonists may favorably affect bone mechanical properties in rats with estrogen deficiency-induced osteoporosis.

Authors:  Aleksandra Janas; Joanna Folwarczna
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-11-28       Impact factor: 3.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.